Phase 2 Thyroid Cancer Trial, Recruiting NCT05989425 Sponsor: Fudan University Condition: Thyroid Cancer
Back to Thyroid Cancer

Phase 2 Thyroid Cancer Trial, Recruiting

NCT05989425
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with locally advanced or metastatic thyroid cancer (specific types include papillary, follicular, poorly differentiated, or particularly differentiated thyroid cancer), confirmed by a tissue or cell sample test
  • Your cancer is considered locally advanced, meaning it has grown into or is pressing on nearby structures (such as nerves, the food pipe, windpipe, voice box, or major blood vessels), is at an advanced surgical stage, or would be very difficult to fully remove with surgery
  • You are between 14 and 75 years old
  • You have at least one tumor that can be measured on a scan
  • You are generally able to carry out daily activities with little or no limitation (confirm with trial site)
  • You are expected to live for at least 12 weeks
  • Your blood, liver, and kidney test results meet certain minimum health levels (confirm with trial site for exact values)
  • If you are able to have children, you must agree to use an approved form of contraception during the study and for 180 days after treatment ends, and must have a negative pregnancy test before starting

Who may not be able to join:

  • You have previously been treated with a type of targeted drug that works by blocking blood vessel growth (anti-angiogenic therapy)
  • You have received any other cancer treatment (such as chemotherapy or radiotherapy) within the 4 weeks before joining, unless it was thyroid hormone suppression therapy
  • You have a known allergy to the study drug
  • You have a history of serious heart or stroke-related conditions
  • Scans show your tumor has grown into major blood vessels, or the medical team thinks this is likely to happen during the study, which could cause dangerous bleeding
  • You have high blood pressure that cannot be adequately controlled with medication (confirm with trial site for exact levels)
  • You have had another type of cancer within the past 5 years (exceptions may apply for certain fully treated skin or cervical cancers — confirm with trial site)
  • The medical team has any other clinical or medical concern that makes participation unsuitable for you

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jiaying Chen, Fudan University

Phone: 86-18017317883

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
4 August 2023
Est. completion
4 August 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

ORR

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov